CCC publication: DNA methyltransferase inhibitor guadecitabine combined with cisplatin and gemcitabine chemotherapy (SPIRE): Randomized expansion phase as neoadjuvant therapy for bladder urothelial carcinoma

Citation: Journal of Clinical Oncology. 2021, 39(6)
Author: Crabb S.J.; Danson S.; Catto J.W.F.; Hussain S.A.; Dunkley D.; Downs N.; Saunders G.; Light M.; Sarwar N.; Enting D.; Jane Birtle A.; El Ghzal A.; Johnson B.; Huddart R.A.; Griffiths G.O.
Abstract: Purpose: Preclinical data indicate that DNA methyltransferase inhibition will circumvent cisplatin resistance in various cancers.